SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to a significant EPS miss attributed to a one-time tax charge, sparking debate about its impact and future performance. The community is analyzing whether the sell-off is an overreaction, considering the company's revenue beat and increased spending on AI and data centers. Some traders view this dip as a buying opportunity, while others are concerned about Meta's spending and the overall market's reaction.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to a significant after-hours drop following its earnings report, with lowered full-year guidance sparking concern. The community is discussing the revenue miss and questioning the justification for the steep decline, while some investors see it as a buying opportunity, anticipating a potential bounce. Broader economic concerns and cost pressures in the restaurant sector are also contributing to the conversation.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to anticipation surrounding earnings, with discussions focusing on Azure's performance and the impact of AI investments. Community members are closely watching guidance and debating whether the stock will surge or face headwinds. Concerns about potential cloud infrastructure spending bubbles and recent Azure outages add to the mix of opinions.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending amid mixed sentiment, with some traders pointing to an EPS miss and concerns about debt, while others highlight strong sales volume and potential for a short squeeze. Community discussions revolve around the company's profitability, sales figures, and upcoming earnings report, with some labeling the stock a "scam" and others anticipating a pump. Analysts' price target reiterations are also being discussed.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet's stock is trending following a positive reaction to news of strong cloud growth, AI advancements, and a JP Morgan price target increase. The community is discussing the potential for further gains, with some eyeing a move to $300 and beyond and continued dominance in the AI space. Upcoming earnings are a key focal point, with investors weighing the potential for continued growth.

Alphabet Inc - Ordinary Shares - Class C

Recent reports of a quantum computing breakthrough and a potential multi-billion dollar cloud deal with Anthropic are driving positive sentiment for $GOOG. The Stocktwits community is closely watching the potential impact on earnings and the competitive landscape, particularly in AI and cloud services. Some traders are expressing concerns about market overextension, while others remain bullish, anticipating further gains.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending as traders discuss a potential breakout and possible squeeze, focusing on accumulation patterns and the need to break the $7-$8 resistance level. Community members are pointing to the low float and growing volume as potential catalysts for a significant upward move. Some traders are also speculating about news related to the company's market cap being undervalued.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending due to concerns surrounding its recent earnings, particularly a significant drop in operating income and margins. The community is debating the effectiveness of the current CEO and the sustainability of the company's pricing strategy amidst layoffs and closures. Discussions also involve the competitive landscape, with some suggesting smaller coffee shops and international players like Luckin Coffee are posing a threat.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to recent earnings reports and raised full-year forecasts, sparking optimism among investors. The community is focused on potential credit and stock upgrades, as well as speculation about a short squeeze. Discussions also involve possible buybacks and debt repayment strategies by the company.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics ($CAPR) is trending as investors anticipate Phase 3 data for their DMD treatment, Deramiocel, with potential for FDA approval. Community discussion revolves around positive trial signals, recent job postings hinting at manufacturing readiness, and the potential of the StealthX exosome platform beyond DMD.  Many bulls are expressing conviction about upcoming results, while some bears remain skeptical, pointing to past regulatory hurdles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR...

Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings

Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.

ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the...

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of...

Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether...

<ul class="summary-bullets"><li>Under the deal, Lilly will commence a tender offer to acquire all of the outstanding shares of Adverum common stock at a per-share price of $3.56, payable in cash at closing, plus milestone payments of up to $8.91 per contingent value right.&nbsp;</li><li>The transaction is expected to close in the fourth quarter of 2025, subject to satisfaction of the closing conditions. &nbsp;</li></ul>Eli Lilly and Company (LLY) said on Friday that it has entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (ADVM) for a total potential per share consideration of up to $12.47.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lilly-to-acquire-adverum-biotechnologies-302593482.html">deal</a>, Lilly will commence a tender offer to acquire all of the outstanding shares of Adverum common stock at a per-share price of $3.56, payable in cash at closing, plus milestone payments of up to $8.91 per contingent value right. The upfront cash payment, however, represents a discount of about 15% from the stock’s closing price on Thursday.The transaction is expected to close in the fourth quarter of 2025, subject to satisfaction of the closing conditions.<h2 class="st-heading-2">Board’s View</h2>Adverum said the transaction was unanimously approved by its board of directors following an evaluation of strategic alternatives and discussions with potential partners and buyers. It added that the board believes the agreement with Lilly is in Adverum's and its stockholders' best interests.The acquisition includes Adverum’s lead product candidate Ixo-vec, a late-stage gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose. The milestone payments in the deal are associated with the development of the gene therapy, including U.S. approval.<h2 class="st-heading-2">Fund Arrangements</h2>Adverum has also entered into a Promissory Note with Lilly in conjunction with the transaction that enables it to receive a loan of up to $65 million from Lilly, drawable in four installments, subject to specified conditions. The loan can be used to support ongoing Ixo-vec clinical trials and registrational development activities prior to the anticipated closing of the transaction, it said.Shares of ADVM soared 3% on Friday morning at the time of writing. On Stocktwits, retail sentiment around ADVM soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ADVM">ADVM stock</a> is down by 7% this year and by about 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gm-reportedly-lays-off-over-200-employees-days-after-raising-2025-earnings-guidance/cLGJFcKR3tb">GM Reportedly Lays Off Over 200 Employees Days After Raising 2025 Earnings Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly To Acquire Adverum Biotechnologies

Under the deal, Lilly will commence a tender offer to acquire all of the outstanding shares of Adverum common stock at a per-share price of $3.56, payable in cash at closing, plus milestone payments of up to $8.91 per contingent value right. 

Equity

Lilly to Acquire Adverum Biotechnologies

Lilly to Acquire Adverum Biotechnologies Lilly to Acquire Adverum Biotechnologies PR Newswire INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 Adverum's lead program, Ixo-vec, is a Phase 3 gene...

Adverum Biotechnologies (ADVM) Receives a Buy from Oppenheimer

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Adverum Biotechnologies (ADVM Research Report), with a...

Buy Rating for Adverum Biotechnologies Based on Promising Ixo-Vec Therapy and Strategic Growth Opportunities

TD Cowen analyst Joseph Thome has maintained their bullish stance on ADVM stock, giving a Buy rating on August 2. Joseph Thome has given his Buy ra...

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Adverum Biotechnologies Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

ADVM
Adverum Biotechnologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ADVM News

ADVMAdverum Biotechnologies Inc